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patients from endoluminal repair or lead to technical diffi-
culties in stent-graft delivery. Anatomical limitations for
the applicability of stent-grafts include a short or wide
neck, severe neck angulation, and tortuous or stenotic
access arteries. The criteria for candidate selection are
evolving, as are the development of improved grafts and
delivery systems. As experience with stent-grafts and
endoluminal techniques increases, more patients with
infrarenal AAA will likely be able to be treated in this man-
ner. Furthermore, a smaller diameter and a more flexible
delivery system could potentially address several of the
anatomical restrictions of stent-graft implantation.
The bifurcated Excluder endoprosthesis (Fig 1; W. L.
Gore and Associates, Flagstaff, Ariz) is a device that allows
for the primary endovascular treatment of an infrarenal
AAA. The initial feasibility (phase I) study was conducted
in the United States, with three investigational centers
enrolling 29 patients. Complications related to prosthesis
deployment did not occur, nor were there any acute con-
versions to open aneurysm repair. Our institution has been
The first widely read description of a prosthetic
endovascular graft for repair of an abdominal aortic
aneurysm (AAA) was written by Parodi et al in 1991.1
Since then, many studies have demonstrated the technical
feasibility and effectiveness for AAA exclusion from the
systemic circulation with an endoluminal stent-graft sys-
tem. Various anatomic features of an AAA exclude many
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Purpose: This report describes our initial experience with the modular, bifurcated Excluder endoprosthesis and its safety
and efficacy in the primary endovascular repair of infrarenal abdominal aortic aneurysms (AAAs).
Methods: AAAs (mean diameter, 58.2 ± 14.3 mm) were repaired in 19 patients with this device between March 1999
and January 2000. The mean age of patients was 71.8 ± 8.4 years (range, 57-86 years). This modular device was
inserted through an 18F introducer sheath placed in one femoral artery, and the contralateral artery was cannulated
with a 12F introducer sheath. All procedures were performed in a standard operating room with angiographic capa-
bilities.
Results: Endograft deployment was successful in all patients. The average surgical time was 135 ± 37 minutes, with a
mean blood loss of 229 ± 138 mL. In eight patients, the use of either aortic or iliac extenders was required for enhanced
sealing or additional length. An external iliac artery dissection occurring at the time of endograft insertion was suc-
cessfully treated with a Wallstent. Type II leaks initially found to be present by means of intraoperative completion
angiography had spontaneously thrombosed by the 1-month follow-up computed tomography scan. There was one
perioperative death (5.3%). Complications included superficial wound infections (n = 3) and a nonfatal myocardial
infarction (n = 1). The mean length of hospital stay was 2.9 ± 1.2 days, and only six patients required intensive care.
Endoleaks were seen in four patients (21%) by means of the 30-day computed tomography scan; three of these
endoleaks had spontaneously sealed at the time of the 6-month follow-up examination (5.5% 6-month endoleak rate).
Aneurysm size did not increase in the patients with leaks.
Conclusion: The Excluder endoprosthesis was an effective means of excluding an infrarenal AAA from the systemic cir-
culation in this selected group of patients. The smaller sheath sizes may increase the pool of potential candidates.
Further study of this device is warranted, and continued assessment of the long-term durability of the device will be
necessary. (J Vasc Surg 2001;33:497-502.)
involved in the multicenter, manufacturer-sponsored,
Food and Drug Administration (FDA)–approved phase II
trial of this endoprosthesis. In this report, we detail our
initial results with the Excluder endoprosthesis for endo-
luminal repair of AAAs.
PATIENTS AND METHODS
Patient selection. Between March 1999 and January
2000, 19 eligible patients (of 56 patients screened) were
part of an FDA phase II multicenter trial with the
Excluder endoprostheses manufactured by W.L. Gore and
Associates. To date, all eligible patients have been men with
an average age of 71.8 ± 8.4 years (range, 57-86 years).
Risk factor profiles were obtained (Table). The protocol
required that all patients have acceptable medical risks for
open aneurysm repair if surgical conversion were to
become necessary. All patients provided informed consent,
and the institutional review board at Emory University
Hospital approved the prospective study protocol.
The study protocol included patients who have an
infrarenal AAA of 4.5 cm or larger with a thrombus-free
proximal aortic neck of 15 mm or larger and angulation of
60° or less. The iliofemoral system had to be able to
accommodate the 18F introducer sheath (ie, outer diam-
eter of 20F equal to the vessel diameter of 6.7 mm).
Furthermore, only one common iliac artery could be
involved with aneurysmal disease, to preserve antegrade
flow in one hypogastric vessel. Patients were excluded
from insertion of the device when they had a ruptured or
mycotic aneurysm, coexisting thoracic aneurysm, recent
myocardial infarction or stroke (< 6 weeks), pulmonary
insufficiency requiring chronic home oxygen therapy, or
renal insufficiency (creatinine level ≥ 2.5 mg/dL). No
other surgical procedures could take place at the same
time or within 30 days before endograft placement. The
exception was embolization of an internal iliac artery in
preparation for the stent-graft procedure.
Preprocedural screening. All patients underwent
abdominal and pelvic computed tomographic (CT) scan-
ning with 3-mm collimation and contrast enhancement
from the celiac artery to the common femoral arteries.
The aortic neck diameter could not be greater than 26
mm because of sizing constraints. Aortography with a cal-
ibrated catheter (Cook, Bloomington, Ind) was per-
formed as a means of evaluating the dimensions, patency,
and tortuosity of the abdominal aorta and branch and
access vessels. All studies were performed within the 6
months before the implantation per the protocol.
Aortic anatomy. The average aneurysm diameter was
58 ± 14 mm (range, 45-95 mm). The mean length of the
proximal neck was 28 ± 9 mm (range, 17-44 mm), and the
mean diameter was 23 ± 2 mm (range, 20-25 mm). The
mean diameter of the left common iliac artery was 11 ± 2
mm (range, 7-17 mm). Similarly, the right common diam-
eter was 11 ± 3 mm (range, 5-20 mm). All diameter mea-
surements were performed with internal vessel diameters.
Nine patients (47%) had one or more iliac arteries that
measured less than 1 cm in diameter. The aneurysms had
an average neck angle of 18 ± 16 degrees (range, 0-52
degrees). Unilateral common iliac aneurysms were present
in five patients, with two aneurysms extending to the iliac
bifurcation.
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Fig 1. Main trunk and ipsilateral limb with attached ePTFE
sleeve. Proximal end of main trunk demonstrates anchoring sys-
tem. Reprinted with the permission of W.L. Gore and Associates.
Fig 2. Bifurcated Excluder endoprosthesis. Reprinted with per-
mission of W.L. Gore and Associates.
Technical aspects. The Excluder endoprosthesis is a
modular system manufactured with an expanded polytetra-
fluoroethylene (ePTFE) prosthesis and is externally sup-
ported by a self-expanding nitinol stent structure (Fig 1).
Angled wire barbs are located at the proximal end of the
main device (trunk-ipsilateral leg component) to provide
additional anchoring support against the aortic wall 
(Fig 2). A radiopaque ring marks the contralateral leg
opening. Radiopaque markers are present to facilitate
proper orientation of the device before deployment. The
contralateral prosthesis is also composed of a tapered
ePTFE tube and a nitinol exoskeleton. The proximal end
fits into the contralateral leg hole in the main device. Both
components of the device have an attached sleeve made of
ePTFE that is sewn closed around the prostheses and
functions to constrain them during positioning. Aortic
and iliac extenders are available. The aortic extenders
allow for 1.5 cm of proximal extension. The iliac extenders
give as much as 4 cm of additional length to either the
ipsilateral or contralateral leg components.
The self-expanding components of the Excluder come
preloaded on delivery catheters that are similar for all com-
ponents. The outer shaft is reinforced with braided stain-
less steel and has two inner tubes, one for the guidewire
and one for the deployment line. The deployment line is
attached to the ePTFE sleeve that is sewn around the pros-
thesis. The deployment line is pulled, releasing the sleeve
and allowing for device self-expansion, to release the pros-
thesis. The trunk-ipsilateral leg component and aortic
extenders are packaged within 18F delivery catheters,
whereas the contralateral leg component and iliac exten-
ders are set on 12F delivery catheters. The delivery
catheters must be introduced through 18F and 12F
sheaths, respectively.
The procedures were performed in a standard operat-
ing room with patients under general anesthesia. The
common femoral arteries were used as access sites and
exposed via bilateral surgical cutdowns. With an angio-
graphic catheter with 1-cm radiopaque markings (Cook),
an arteriogram was first performed to verify AAA dimen-
sions and to determine how to position the device.
Fluoroscopic guidance (OEC 9600, OEC Medical
Systems, Thousand Oaks, Calif) was used for placement of
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the endograft in the infrarenal aorta. After the deployment
of the main trunk-ipsilateral limb component, an occlu-
sion balloon was inflated within the proximal attachment
system. Next, the contralateral leg opening was cannulated
in a retrograde fashion. The contralateral leg component
was inserted and positioned so that there was 3.0 cm of
overlap between the components. Additional procedures
and extenders were added when necessary, with balloon-
ing of all areas of overlap and the distal attachment sites.
A completion angiogram was obtained with prolonged
digital subtraction angiography filming as a means of
detecting endoleaks.
We used the definition of technical success described by
the Society for Vascular Surgery/International Society for
Cardiovascular Surgery Ad Hoc Committee on Reporting
Standards for Endovascular AAA Repair.2 In brief, 30-day
technical success is defined on an intent-to-treat basis to be
successful endograft deployment, without death, need for
standard aortic reconstruction for 30 days, or evidence of
persistent (> 48 hours) endoleak. Clinical success includes
those patients who at 6 months after implantation have a
persistent endoleak that has spontaneously sealed and with
no evidence of aneurysm enlargement. Other outcomes
analyzed included successful graft deployment, irrespective
of the presence or absence of endoleak, surgical time, oper-
ative blood loss, duration of stay in an intensive care unit,
length of hospital stay, and patient survival. CT scanning at
1, 6, and 12 months was used as a means of assessing the
complete exclusion of the AAA.
RESULTS 
Technical and clinical success. Endovascular stent-
graft deployment was successful in all 19 patients enrolled
in the phase II trial. No intraoperative deaths occurred.
The total operative time averaged 135 ± 37 minutes;
blood loss averaged 229 ± 138 mL, and the amount of
intravascular contrast was 233 ± 82 mL. Patients averaged
2.9 ± 1.2 postoperative days of hospital stay, with 0.6 ± 1
day in an intensive care unit. No adverse events specifically
related to stent-graft deployment were encountered.
Secondary endovascular procedures. Two patients
required embolization of one hypogastric artery before
stent-graft placement so that common iliac artery
Patient characteristics and operative risk factors
Characteristic Value (%)
Coronary artery disease* 11 (58)
Coronary revascularization† 10 (53)
Earlier acute myocardial infarction 8 (42)
Peripheral vascular disease 3 (16)
Congestive heart failure 2 (11)
Hypertension 9 (47)
Preoperative serum creatinine level (mg/dL)‡ 1.2 ± 0.4 (range, 0.6-2.0)
Aortic aneurysm diameter‡ 58 ± 14
*Value does not include one patient who had received a heart transplant for severe cardiomyopathy.
†Either coronary artery bypass graft or percutaneous transluminal coronary angioplasty.
‡Values are given with the mean ± SD.
aneurysms could be excluded. One patient had an intra-
operative external iliac artery dissection during sheath
advancement that was recognized after stent deployment
and covered successfully with a Wallstent (Schneider,
Minneapolis, Minn). Two patients had distal movement of
the proximal attachment site at the time of the procedure.
In both cases, the movement was thought to be caused by
significant neck angulation. One patient had a single aor-
tic extender placed, whereas the other patient had three
successive aortic extenders placed to ensure seating of the
endograft below the renal arteries after significant distal
movement. Additionally, six patients had five common
iliac artery aneurysms covered with iliac extenders.
Predeployment angioplasty was performed in both com-
mon iliac arteries in one patient to allow uncomplicated
passage of the delivery catheters. No leakage between
modular components was observed in these patients.
Endoleak rate. The 30-day technical success rate, as
defined by means of the Society for Vascular
Surgery/International Society for Cardiovascular Surgery
reporting standards, was 79%. With completion angiogra-
phy, one endoleak was observed. Contrast extravasation
did not appear to be related to the attachment sites or to
the intergraft junction. Therefore, we elected to observe
the endoleak, which subsequently had resolved by the time
of the 1-month surveillance CT scan. At the first scheduled
CT scan (1month follow-up visit), three leaks (17%) were
discovered that were not seen at the time of graft implan-
tation with the completion angiogram. All three appeared
to be branch vessel leaks; no contrast was seen at either the
proximal or distal attachment sites. We chose to observe
the endoleaks in the absence of any increase in size of the
native aneurysm sac. Two of these endoleaks had sponta-
neously resolved by 6 months, with no significant (≥ 3 mm
per study protocol) change in aneurysm size. One patient
underwent angiography by means of which retrograde flow
from a patent inferior mesenteric artery into the aneurysm
sac was demonstrated. Successful embolization was per-
formed. Thus, the clinical success rate at 6 months was 94%
(for 18 living patients).
Patient outcomes. A mean follow-up of 9.8 ± 3.6
months (range, 2-12 months) was completed on the
patients who underwent implantation. Per the protocol,
if no endoleak was suggested at the time of the 1-year
follow-up visit, the patient did not return until 2 years
after implantation. One patient died suddenly 4 weeks
after hospital discharge; no endoleak (30-day mortality
rate, 5.3%) or any evidence of native aneurysm rupture
was demonstrated by means of a CT scan 2 days before
his death. The family of this patient did not want an
autopsy performed. The total morbidity rate was 22% (4
of 19). Major morbidity occurred in one patient (5.3%).
This patient had a non-Q wave myocardial infarction
after implantation. He was treated medically and dis-
charged home on day 3. In addition, there were three
minor morbidities consisting of superficial inguinal
wound infections and associated leg edema. All were suc-
cessfully treated on an outpatient basis with local wound
care and antibiotic therapy; thus, the hospital stay was
not prolonged.
During the follow-up period, we observed no late
endoleak development, stent-graft migration, or anchor-
ing barb fracture. Furthermore, there has been no
aneurysm enlargement or graft limb thrombosis.
DISCUSSION
The use of endovascular grafts for the repair of
infrarenal AAAs is a rapidly developing field, with several
stent-graft systems being tested and two now available for
commercial use in the United States. Several investigators
have reported the feasibility of stent-graft placement with
various commercial and on-site manufactured devices, all
with high technical success rates that range from 86% to
100% and excellent short-term follow-up.2-8 On the basis
of early results of the phase II trial at our institution,
endovascular repair of an AAA with the Excluder endo-
prosthesis appears to be both safe and effective. We report
our 100% deployment success with the Excluder endo-
prosthesis and our 79% 30-day technical success rate. No
conversion to open surgical repair and no complications
specifically related to device deployment occurred in our
series. Although two patients required additional aortic
extender cuff placement because of distal migration of the
main device, no untoward event occurred as a result. The
patients studied were a highly select group with little high-
risk comorbidity that would have prohibited conventional
repair. Data were collected under the rigorous require-
ments of an FDA phase II clinical trial, and we had all
patients return for scheduled follow-up radiologic exami-
nation. The technical success of this series was consistent
with the success we have had after implantation of other
commercially made stent-graft systems.
Additionally, the complication rate in the patients who
underwent implantation in this trial was low, consistent
with that reported by other investigators. There was one
death, which occurred in a patient with a history of cardiac
disease and arrhythmias. Four weeks after discharge from
the hospital after stent-graft placement, he died suddenly
in his home. No endoleak, aneurysm enlargement, or evi-
dence or leakage from the native aneurysm sac was
demonstrated by means of the 1-month CT scan that was
performed 2 days before his death. However, we cannot
exclude the possibility of a rupture of the native aneurysm
sac, because no autopsy was performed. Other complica-
tions in this series included a non-Q wave myocardial
infarction, which was treated with medical management,
and three superficial groin wound infections, none of
which prolonged the hospital stay or required rehospital-
ization. The patients in this series stayed in the hospital an
average of 2.9 days, with only 32% requiring time in the
intensive care unit.
The inability to completely exclude an AAA with a
stent-graft is often considered to be a technical failure.
Thus, any endoleak under observation, such as the three
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reported herein, would be determined to be a technical
failure. We define a technical failure as an unsuccessful
stent-graft deployment with procedure termination or
conversion to an open AAA repair. Similarly, an endoleak
at either proximal or distal attachment sites that was rec-
ognized and not corrected would constitute a technical
failure. Resch and colleagues have reported that endoleaks
originating from aortic side branch vessels are not believed
to carry an increased risk of aneurysm rupture, because
patency of these collaterals is not directly related to
growth of the aneurysm sac.3 Large endoleaks can often
be treated with additional endovascular procedures.
Fortunately, other authors have reported that 29% to 50%
of early postoperative endoleaks spontaneously throm-
bose.4-7 Therefore, we choose to closely observe branch
vessel endoleaks with frequent follow-up CT scans, as dic-
tated by the phase II trial protocol. Such close observation
with radiologic examination is the standard-of-care for
patients at our institution who undergo implantation with
commercially available devices also. Nonetheless, the true
significance of an endoleak is not known. Also unknown is
the relationship of a leak to the risk of aneurysm rupture,
even in the absence of an increase in aneurysm size.
There are several characteristics that are specific to the
Excluder endoprosthesis and deserve discussion. First, a
deployment line is attached to an ePTFE sleeve that is sewn
around the prosthesis. For the stent-graft to be released,
this line is pulled in a single movement, the sleeve
“unzips”, and the device, which had been previously con-
strained in the sleeve, rapidly deploys. This mechanism of
deployment is advantageous because of its simplicity. When
multiple sequential steps for endograft placement are
required, the risk of operator-related mistakes may be
increased. Furthermore, such rapid deployment does not
require lowering of the systemic blood pressure before
release. Because patients with an AAA often have cardiac
disease (58% of patients in our series), maintenance of
hemodynamic stability is crucial. Hypotension, even to a
minor degree, may be detrimental to a patient with coro-
nary stenosis or valvular disease. However, this rapid
deployment process does not allow for repositioning of the
device. Most other stent-graft delivery systems involve a
sheath or graft cover that surrounds and protects the
device, which permits adjustments of the position even
after the device is partially deployed. Once the final posi-
tion of the stent-graft is deemed satisfactory, the entire
stent-graft is fully deployed. This deliberate deployment
process may allow for subtle adjustments of the device
position. However, the Excluder deployment system does
not allow for any readjustment of position. Therefore, the
physician doing the implanting must be exact in position-
ing before pulling the deployment line or be prepared to
add secondary endovascular techniques when needed. For
example, one patient in this series needed three successive
aortic extenders to approximate the graft to the level of the
renal arteries after distal movement of each added compo-
nent. Because positioning is crucial to successful and safe
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Volume 34, Number 3 Bush et al 501
delivery, it is beneficial to have the ability to check and
adjust endograft position before complete deployment.
The relatively smaller size of the Excluder, in contrast
to other currently available stent-graft systems, is a signif-
icant advantage. The main device is introduced through
an 18F sheath, whereas a 12F sheath is used for the con-
tralateral limb. Though we have not performed direct
arterial puncture yet, this may be entirely feasible for the
contralateral sheath. In this manner, only 1 incision would
need to be made, and the contralateral puncture site might
be closed with a commercially available hemostatic device.
More clinically relevant, however, is the applicability of a
smaller, more flexible and trackable system to a wider array
of patients. This device may be more suitable for patients
with tortuous iliac arteries or smaller caliber access arter-
ies. For example, three patients who underwent implanta-
tion in this series had small caliber arteries, ranging from
5 to 7 mm, at the selected distal landing site. We acknowl-
edge that these three patients had smaller diameter vessels
than the minimum (1 cm) recommended by the Excluder
clinical trial; however, the vessel size did not prohibit
inclusion into the trial. Nonetheless, difficulty in travers-
ing these smaller vessels did not occur. On the basis of this
limited experience, it appeared that this smaller caliber
device could accommodate patients with narrower iliac or
femoral arteries, a feature commonly found in female
patients. A recent study by Sandgren et al8 examined the
size of the common femoral artery with ultrasound imag-
ing and found that women had a significantly smaller com-
mon femoral artery diameter. In patients older than 60
years, the mean diameter of the common femoral artery
was 9.2 mm in women, compared with 10.4 mm in men.
The naturally smaller vessels in women have often pre-
cluded the placement of the larger stent-graft devices, in
our experience. We think that a device with a relatively
low-profile delivery system may allow for patients with
smaller femoral arteries to undergo endovascular AAA
repair.
The Excluder is a fully supported stent-graft that may
minimize limb kinking and twisting during deployment or
with aneurysm remodeling by providing longitudinal sup-
port. However, the risk and incidence of endoleak at the
connections between modular components is unknown.9-11
Undoubtedly, close follow-up of these patients is neces-
sary to ensure the long-term efficacy of this modular stent-
graft device.
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